Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 5/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508198 | 0.86 | CPB2 (0.48) | CPB1CPB2NPC1RAB9APOLB | |
| SCHEMBL5254959 | 0.85 | ATR (0.44) | CPB1CPB2CYP4F2CYP4A11VNN1 | |
| SCHEMBL4520181 | 0.82 | CPB2 (0.45) | CPB1CPB2NPC1RAB9AVNN1 | |
| SCHEMBL4515230 | 0.81 | CPB2 (0.57) | CPB1CPB2 | |
| SCHEMBL4493363 | 0.79 | CPB2 (0.55) | CPB1CPB2 | |
| SCHEMBL4501538 | 0.79 | CPB2 (0.43) | CPB1CPB2NPC1 | |
| SCHEMBL4506948 | 0.78 | GAA (0.46) | CPB2NPC1POLB | |
| SCHEMBL4521167 | 0.77 | CPB2 (0.57) | CPB1CPB2 | |
| SCHEMBL4500125 | 0.77 | CPB2 (0.43) | CPB1CPB2POLB | |
| SCHEMBL4497407 | 0.77 | LMNA (0.44) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | METAP1, MPST, DNPEP | CPB1 34/4885SPHK2 1608/4885CPB2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.